Navigation Links
BiondVax Receives Additional Grant Approval
Date:2/18/2016

NESS ZIONA, Israel, February 18, 2016 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that the National Authority for Technological Innovation (NATI), formerly known as the Office of the Chief Scientist, agreed to fund up to 40% of a NIS 3.6 million (US$920,000) project towards ongoing development of the Company's Universal Flu Vaccine.

Currently undergoing late Phase 2 clinical trials, BiondVax's vaccine has shown significantly increased effectiveness against multiple seasonal and pandemic flu strains when compared to today's existing flu vaccines.  With today's grant approval, NATI has, since 2006, granted $5.5M to BiondVax. The non-dilutive grants are repayable from royalties generated from future sales of BiondVax's vaccine, once available on the market.

Ron Babecoff, CEO of BiondVax commented, "The continued support of our program by NATI represents a strong and ongoing vote of confidence in BiondVax and what we are aiming to achieve. They were impressed with the positive results from our five completed clinical trials to-date, and strongly support our current and planned activities."

About BiondVax Pharmaceuticals Ltd. 

BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit http://www.biondvax.com.

Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, the timing of the receipt of the grant funds, risks inherent in the development and commercialization of potential products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements. 

For further information, please contact:

Company Contact
Joshua Phillipson
Business Development  Manager
+972-8-930-2529 x5105
j.phillipson@biondvax.com

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
kenny@biondvax.com


'/>"/>
SOURCE BiondVax Pharmaceuticals Ltd.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. BiondVax Pharmaceuticals Ltd. Announces a Closing of Over-Allotment Option
2. BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults
3. Independent Results Show that BiondVaxs Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic
4. BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference
5. BiondVax to Present on October 8 at the Aegis Growth Conference
6. Biondvaxs Universal Flu Vaccine Receives Additional US Patent
7. IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit
8. Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System
11. BioElectronics Receives Working Capital Infusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2019)... ... 2019 , ... Dr. Leonard Bley at NY LASIK is proud ... (Small Incision Lenticule Extraction) located in their state-of-the-art Manhattan surgery center. NY LASIK is ... area. SMILE is a one-step, one laser procedure that is more minimally invasive than ...
(Date:8/19/2019)... DELRAY BEACH, Fla. (PRWEB) , ... August 19, ... ... Treatment Center will be hosting their 2nd Annual National Sports Summit, August ... addiction experts, former athletes, and clinical leaders from all major professional sports programs ...
(Date:8/19/2019)... ... August 19, 2019 , ... The International Association ... of excellence within the field of treatment for eating disorders, recommends membership for ... others who have a similar mission. , Founded in 1985, the iaedp™ ...
Breaking Medicine Technology:
(Date:8/25/2019)... , ... August 24, 2019 , ... ... honored to be the recipient of The Talk Awards 2019 . The ... 5-star rating in the Talk Awards’ health and medical category based on customer ...
(Date:8/23/2019)... (PRWEB) , ... August 22, 2019 , ... Williamson Memorial ... milestone for any health care organization but especially for community hospitals like WMH, which ... on its long-standing role in the community, it’s also taking steps to ensure it’s ...
(Date:8/21/2019)... ... August 21, 2019 , ... CBD has officially entered ... accompanying this announcement is available at: https://youtu.be/D-65LmBhJhU , CBD, the non-intoxicating ... be found on the internet, wellness catalogs, small specialty shops, and now, after ...
(Date:8/21/2019)... ... August 21, 2019 , ... Photoprotective Technologies (PPT) has just received US patent ... currently used in skincare products such as creams or makeup and is distributed by ... need to protect the skin from blue light as well as UV. , ...
(Date:8/19/2019)... ... August 19, 2019 , ... Nearly seven years after the ... , the authorized retailer will change its corporate name to ‘EmStore.com’. , In ... providing Eminence Organic Skin Care facials and treatments. DeVries noticed there was an ...
Breaking Medicine News(10 mins):